Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-09-30

FDA Approved: RYALTRIS — Supplemental Application (HIKMA SPECIALTY USA INC.)

View source ↗

Summary

The FDA approved a supplemental application for RYALTRIS, a combination nasal spray of olopatadine hydrochloride and mometasone furoate, submitted by Hikma Spec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RYALTRIS (OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE)

Snippet

SUPPL AP for RYALTRIS (OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE)